Novel drug candidates for blast phase chronic myeloid leukemia from high-throughput drug sensitivity and resistance testing

por Pietarinen, P O, Pemovska, T, Kontro, M, Yadav, B, Mpindi, J P, Andersson, E I, Majumder, M M, Kuusanmäki, H, Koskenvesa, P, Kallioniemi, O, Wennerberg, K, Heckman, C A, Mustjoki, S, Porkka, K
Publicado 2015

Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia

por Ilander, M, Olsson-Strömberg, U, Schlums, H, Guilhot, J, Brück, O, Lähteenmäki, H, Kasanen, T, Koskenvesa, P, Söderlund, S, Höglund, M, Markevärn, B, Själander, A, Lotfi, K, Dreimane, A, Lübking, A, Holm, E, Björeman, M, Lehmann, S, Stenke, L, Ohm, L, Gedde-Dahl, T, Majeed, W, Ehrencrona, H, Koskela, S, Saussele, S, Mahon, F-X, Porkka, K, Hjorth-Hansen, H, Bryceson, Y T, Richter, J, Mustjoki, S
Publicado 2017